65025-95-8

Usage

Uses

Intermediate in the preparation of prostaglandin derivatives

InChI:InChI=1/C19H34O5Si/c1-19(2,3)25(4,5)22-12-14-13-10-17(20)23-15(13)11-16(14)24-18-8-6-7-9-21-18/h13-16,18H,6-12H2,1-5H3/t13-,14-,15+,16-,18?/m1/s1

Upstream product

• 69222-61-3 2-oxo-6-syn-(hydroxymethyl)-7-anti-(tetrahydropyran-2-yloxy)-cis-bicyclo<3.3.0>octan-3-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 110-87-2 3,4-dihydro-2H-pyran 
• 58707-50-9 (3aR,4S,5R,6aS)-4-((tert-butyldimethylsilyloxy)methyl)-5-hydroxyhexahydro-2H-cyclopenta[b]furan-2-one 
• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 31752-99-5 (-)-Corey lactone 5-(4-phenylbenzoate) 
• 165876-61-9 (3aR,4S,5R,6aS)-4-((tert-butyldimethylsilyloxy)methyl)-2-oxo hexahydro-2H-cyclopenta[b]furan-5-yl biphenyl-4-carboxylate 
• 288-32-4 1H-imidazole 
• 62939-82-6 (3aR,4S,5R,6aS)-5-(acetyloxy)-4-[(acetyloxy)methyl]hexahydro-2H-cyclopenta[b]furan-2-one 
• 26054-46-6 (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one 
• 62447-84-1 (3aR,4S,5S,6R,6aR)-4-Benzyloxymethyl-6-iodo-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-one 
• 31767-37-0 6-Benzyloxymethyl-7-hydroxy-8-iodo-2-oxabicyclo<3.3.0>octan-3-one 
• 32233-38-8 3α,5α-dihydroxy-2β-(benzyloxymethyl)cyclopentane-1α-acetic acid γ-lactone 3-tetrahydropyran-2-yl ether 

Downstream Products

• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 67788-45-8 (1S,5R,6S,7R)-7-(tetrahydropyran-2-yl)oxy-6-(tetrahydropyran-2-yl)oxymethyl-2-oxabicyclo[3.3.0]octan-3-one 
• 443796-72-3 Toluene-4-sulfonic acid (E)-6-[(1R,2S,3R,5R)-2-(tert-butyl-dimethyl-silanyloxymethyl)-5-chloro-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hex-4-enyl ester 
• 58682-80-7 misoprostol 
• 62137-77-3 (Z)-7-[(1R,2R,3R,5S)-5-Acetoxy-2-hydroxymethyl-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hept-5-enoic acid methyl ester 
• 61302-47-4 methyl 7-((1R,2S,3R,5S)-5-acetoxy-2-hydroxymethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)heptanoate 
• 127127-92-8 {2-[(1R,2R,3aS,7aS)-2-Hydroxy-1-((E)-(R)-3-hydroxy-4-methyl-4-phenoxy-pent-1-enyl)-2,3,3a,6,7,7a-hexahydro-1H-inden-5-yl]-ethoxy}-acetic acid 
• 127056-38-6 {2-[(1R,2R,3aS,7aS)-2-Hydroxy-1-((E)-4-methyl-3-oxo-4-phenoxy-pent-1-enyl)-2,3,3a,6,7,7a-hexahydro-1H-inden-5-yl]-ethoxy}-acetic acid tert-butyl ester 
• 127127-89-3 {2-[(1R,2R,3aS,7aS)-1-((E)-4-Methyl-3-oxo-4-phenoxy-pent-1-enyl)-2-(tetrahydro-pyran-2-yloxy)-2,3,3a,6,7,7a-hexahydro-1H-inden-5-yl]-ethoxy}-acetic acid tert-butyl ester 
• 117028-17-8 {2-[(1R,2R,3aS,7aS)-1-((E)-3-Hydroxy-4-methyl-4-phenoxy-pent-1-enyl)-2-(tetrahydro-pyran-2-yloxy)-2,3,3a,6,7,7a-hexahydro-1H-inden-5-yl]-ethoxy}-acetic acid tert-butyl ester 
• 127127-90-6 {2-[(1R,2R,3aS,7aS)-2-Hydroxy-1-((E)-(R)-3-hydroxy-4-methyl-4-phenoxy-pent-1-enyl)-2,3,3a,6,7,7a-hexahydro-1H-inden-5-yl]-ethoxy}-acetic acid tert-butyl ester 
• 127127-91-7 {2-[(1R,2R,3aS,7aS)-2-Hydroxy-1-((E)-(S)-3-hydroxy-4-methyl-4-phenoxy-pent-1-enyl)-2,3,3a,6,7,7a-hexahydro-1H-inden-5-yl]-ethoxy}-acetic acid tert-butyl ester 
• 142102-19-0 <1S-(1α,2β,3α)>-2-<2-<<(tert-butyldimethylsilyl)oxy>methyl>-5-methenyl-3-(tetrahydropyranyloxy)cyclopentanyl>ethanol triphenylmethyl ether 
• 142066-65-7 <1S-(1α,2β,3α,5α)>-2-<2-<<(tert-butyldimethylsilyl)oxy>methyl>-5-<<(methylsulfonyl)oxy>methyl>-3-(tetrahydropyranyloxy)cyclopentanyl>ethanol triphenylmethyl ether 

Relevant academic research and scientific papers

The preparation method of the ruby's forefront

The invention relates to a preparation method of lubiprostone, and concretely relates to a preparation method of highly pure lubiprostone represented by formula (I). The method comprises the steps of reducing an initial compound, oxidizing, and hydrolyzing in order to obtain a target compound. Compared with other methods, the method provided by the invention has the advantages of good process reappearance, simple operation, high yield, low cost, high purity of the above obtained product, suitableness for industrialized production, and very high economic benefit.

Discovery of novel seven-membered prostacyclin analogues as potent and selective prostaglandin FP and EP3 Dual Agonists

A novel series of prostaglandin analogues with a seven-membered ring scaffold was designed, synthesized, and evaluated for the functional activation of prostaglandin receptors to identify potent and subtype-selective FP and EP3 dual agonists. Starting fro

A process for the preparation of intermediates useful in the ruby's forefront, preparation method thereof and through its preparation ruby's forefront method

The invention relates to an intermediate for preparing lubiprostone, a preparation method of the intermediate and a method for preparing the lubiprostone through the intermediate, in particular to a compound as shown in a formula V for preparing the lubiprostone (as shown in a formula I), a preparation method of the compound and a method for preparing the lubiprostone through the compound. The method comprises the following steps: performing reduction treatment on the compound as shown in the formula V, performing selective deprotection and hydroxyl oxidation to obtain a compound as shown in a formula II, and performing hydroxyl deprotection on the compound as shown in the formula II to prepare the lubiprostone as shown in the formula I. The method is easy and convenient to operate, high in synthetic yield and suitable for large-scale production.

Before preparing a Lima intermediate row element, method for preparing the same and before the Lima row element through its method of preparation

An intermediate of formula (V) used for preparing limaprost of formula (I), preparation method thereof, and preparation method of limaprost therefrom. The present preparation method of limaprost from the intermediate of formula (V) includes: reduction of the compound of formula (V), followed by protection, deprotection and oxidation of hydroxyl group to provide the compound of formula (II), then deprotecion of hydroxyl group and/or carboxyl group of the compound of formula (II) to provide limaprost of formula (I).

BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES

Provided is a compound which has strong and sustaining intraocular pressure lowering action and, further, has no fear of side effect on eyes. Since a compound represented by the formula (I): wherein definition of each group is as described in the specific

Corey lactone as key precursor for a facile synthesis of novel 1,2,3-triazole carbocyclic nucleosides via Click Chemistry

Corey lactone (2) and Click Chemistry allowed for an efficient and facile approach to the synthesis of novel 1,2,3-triazole carbocyclic nucleosides (11 and 17) in good overall yields.

BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES

Provided is a compound which has strong intraocular pressure lowering action and has no side effect on eyes such as ocular stimulating property, humor protein rise etc. Since a compound represented by the formula (I): (wherein definition of each group is

BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and,

A practical synthesis and biological evaluation of 9-halogenated PGF analogues.

A series of 9-halo PGF analogues 1-2 and 5-13 were synthesized and biologically evaluated. Among the compounds, 2 was the best EP2-receptor agonist. A practical method of synthesizing 2 via the Julia olefination of an aldehyde 3 with an optically active sulfone 4, which was prepared by Sharpless asymmetric epoxidation of 15, was developed. Other 9-halogenated PGF analogues were synthesized essentially by the same procedure and evaluated. The absolute configuration of 16-OH of 2 was determined as S by the X-ray analysis of a salt consisting of a 1/1 molar ratio of 2 and L-lysine.

Prostanoids: Synthesis of enantiomers of 15-deoxy-16-hydroxy-16-methylprostaglandin E1

Four optically pure isomers of methyl 11,16-dihydroxy-16-methyl-9-oxoprost-13-enoate (1a-1d) were synthesized using an approach reverse to the classical Corey procedure, the key intermediates being the easily accessible (-)- and (+)-enantiomers of the Corey lactone, 2a and 2b.